Kraig announces production breakthrough in ‘spider silk’

ANN ARBOR — Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB), the developer of gene splicing technology that creates silkworm silk with the strength of spiderwebs, announced a milestone completion of more than 2,500 microinjections using its new spider silk DNA synthesis methodology.

This new method allows for faster creation of larger and more complex spider silk proteins. Larger and more complex proteins are believed to produce improved silk strength, toughness, and elasticity. The company said the improved recombinant spider silk fibers will allow it to target an expanded set of end market applications.

To support this expanded research and development capability, the Company added two laboratory staff for increased testing throughput. The additional lab staff members have been trained and have conducted the majority of the microinjection effort.

By implementing this new validated protocol and completing these initial microinjections, Craig said it is looking forward to creating new transgenics, at its research headquarters, with a shorter development cycle and enhanced materials performance. The transgenics created using the new protocols are expected to be transitioned into the commercial production process at Prodigy Textiles, the company’s recently announced Vietnamese subsidiary.

“Thanks to our lab and production teams’ considerable collaborative effort, this new methodology has already demonstrated the potential to significantly reduce our development timelines,” said Kraig COO Jon Rice. “To see it put into practice so quickly and to have already completed the first 2,500 test microinjections is very impressive. I look forward to seeing this capability enable the next generation of recombinant spider silk fibers.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, visit www.KraigLabs.com/newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *